Shionogi & Co. reported that its pill-based Covid-19 treatment did not meet the primary endpoint in a global late-stage trial. The drug, known as Xocova, demonstrated a potent antiviral effect but failed to show a statistically significant reduction in 15 common symptoms of the illness. However, if approved, the drug was expected to generate $2 billion in annual sales. The company will collaborate with regulatory bodies to explore the possibility of making the drug available.